Institutional members access full text with Ovid®

Share this article on:

MOVEMENT DISORDERS

Soman, Teesta; Lang, Anthony E.

doi: 10.1212/01.CON.0000348883.62435.75
Article

This chapter will outline the clinical features, diagnostic and management strategies, and issues relating to transitional care of pediatric-onset movement disorders and will provide insights important for the recognition of adult-onset expression of disorders more typically considered to be of pediatric onset. In addition, recognition of familial risk and the methods for diagnosis of presymptomatic family members will be presented.

Movement disorders in children are uncommon and thus are challenged by limited experience of pediatric care providers in the accurate diagnosis of etiology, correct characterization of the clinical phenotype, knowledge of pharmacologic interventions, and limited access to, and experience with, neurosurgical options for care. In this chapter, we will highlight movement disorders that have onset in childhood, with an emphasis on disorders that manifest throughout the lifetime.

By definition, movement disorders are conditions that include involuntary movements that are abnormal in initiation, implementation, velocity, frequency, or posture. They are classified broadly into hyperkinetic (dystonia, myoclonus, chorea, dyskinesias, tremor, tics) and hypokinetic (parkinsonism) disorders. Abnormal movements can be difficult to define, and the diagnosis involves pattern recognition and a qualitative appreciation of the movement. The clinician must first describe the phenomenology of the movements before attempting to classify them.

Relationship Disclosure: Dr Soman has received personal compensation for activities with Santhera Pharmaceuticals. Dr Lang has received personal compensation for activities with Biovail Corporation, Boehringer Ingelheim, Cephalon, Inc., Ceregene, Eisai Inc., H. Lundbeck A/S, Medtronic, Inc., NeuroMolecular Pharmaceuticals, Novartis, Solvay, Taro Pharmaceutical Industries Ltd, and Teva. Dr Lang has received research support from the Canadian Institutes of Health Research, the Dystonia Medical Research Foundation, The Michael J. Fox Foundation for Parkinson's Research, the National Parkinson Foundation, the Ontario Problem Gambling Research Center, the Parkinson's Disease Foundation, and Taro Pharmaceutical Industries Ltd.

Unlabeled Use of Products/Investigational Use Disclosure: Drs Soman and Lang have nothing to disclose.

© 2009 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website